Methylcobalamin Injection

Pharmacology (1) Methylcobalamin is an endogenous coenzyme B12. It plays an important role as a coenzyme of methionine synthase in the transmethylation reaction of homocysteine to methionine. (2) Methylcobalamin is easily transferred to the organelles of nerve cells, thereby promoting the synthesis of nucleic acids and proteins. Methylcobalamin is more easily transferred into the organelles of rat nerve cells than cyanocobalamin. In experiments on mouse brain cells and spinal cord nerve cells, it participates in the process of synthesizing thymidine from deoxyuridine, promoting the utilization of folic acid and the metabolism of nucleic acids. Moreover, methylcobalamin can promote the synthesis of nucleic acids and proteins in rats more than cobalamin. (3) Promotes intra-axonal transport and axonal regeneration. It can normalize the transport of axonal structural proteins in the sciatic nerve cells of rats with diabetes caused by streptozotocin. In the drug-induced neurological disorders (rat and rabbit) caused by doxorubicin, acrylamide, and vincristine, as well as the axonal degeneration mouse model, the neurological disorders of naturally occurring diabetic rats can inhibit the appearance of degenerated nerves in neuropathology and electrophysiology. (4) Promote the formation of myelin (phospholipid synthesis). Compared with adenosylcobalamin, it can promote the synthesis of phosphatidylcholine, the main structure of myelin, thereby improving the formation of myelin (rat). (5) Restore the transmission delay of synapses and the reduction of neurotransmitters. In the experiment of sciatic nerve scraping, it increases the excitation of nerve fibers and thus restores the induction of terminal potential (rat). In addition, it can normalize the low amount of acetylcholine in the brain of rats fed with choline-deficient bait. (6) Promote the maturation and division of erythroblasts and improve anemia. Vitamin B12 deficiency may lead to megaloblastic anemia. This drug promotes the synthesis of nucleic acids in the bone marrow and the maturation and division of erythroblasts, increasing the production of red blood cells. This drug can quickly restore the red blood cell count, hemoglobin and hematocrit values of rats that were reduced due to B12 deficiency. Toxicology 1. Acute toxicity LD50 (mg/kg) Animal species Mouse Rat Rabbit Dog Administration route Oral 1000500 Intravenous injection 66633360200 2. Subacute toxicity Dogs were intravenously injected for 90 days at 0.5, 5.0 and 50.0 mg/kg/day. In each administration group, there were no special changes in general symptoms, body weight, blood and organ weights. In pathological histological examination, microscopic observation revealed that the eosinophilic granules increased in the epithelial cells of the proximal urinary tubules of the kidneys at a dose of 50.0 mg/kg, and an increase in lysosomes was found by electron microscopy. There were no changes in other organs. 3. Chronic toxicity: Dogs were intravenously injected with 0.5, 5.0, and 50.0 mg/kg/day for 12 months. In each administration group, there was no change in general symptoms, body weight, blood and organ weight. In pathological histological examination, microscopic observation revealed that eosinophilic granules increased in the epithelial cells of the proximal urinary tubules of the kidneys at a dose of 5.0 mg/kg or more. Electron microscopic observation revealed an increase in lysosomes. In the 50.0 mg/kg test, an increase in lysosomes in the glomerular mesangial cells and Kupffer cells in the liver were found. 4. Reproductive test: In rats, intravenous injection of 0.5, 5.0, and 50.0 mg/kg/day before and during early pregnancy, organ formation, perinatal period, and lactation period, showed no abnormalities or teratogenic effects on the fetuses and newborns.

Methylcobalamin.

1. Used for peripheral neuropathy. 2. Treatment of megaloblastic anemia caused by vitamin B12 deficiency.

1. For adults with peripheral neuropathy, take 0.5 mg once, 3 times a week, intramuscularly or intravenously, and the dosage can be increased or decreased according to age and symptoms. 2. For adults with megaloblastic anemia, take 0.5 mg once, 3 times a week, intramuscularly or intravenously. After about two months of administration, 0.5 mg can be given once every 1 to 3 months as a maintenance treatment.

1. Serious adverse reactions (frequency unknown) Allergic reactions: may cause allergic reactions such as decreased blood pressure and difficulty breathing. Patients should be closely observed. If such reactions occur, medication should be discontinued immediately and appropriate measures should be taken. 2. Other adverse reactions (1) Allergic reactions: rash (0.1%). If these adverse reactions occur, medication should be discontinued. (2) Others: headache, fever (0.1%); sweating, pain and nodules at the intramuscular injection site (frequency unknown). If these adverse reactions occur, medication should be discontinued.

It is contraindicated for those who are allergic to this product and its ingredients.

Precautions for children: Not yet clear. Precautions for pregnancy and lactation: The safety of using this drug in pregnant and lactating women is not yet clear. Precautions for the elderly: Not yet clear.

Not yet clear.

Keep in a sealed container and away from light.

1ml:0.5mg

24 months.

Qinghai Chenfei Pharmaceutical Co., Ltd.

• Founded in:

  2006-12-27

• Address:

  No. 141, Bayi East Road, Dongchuan Industrial Park, Xining City, Qinghai Province

• Tax NO.:

  91632900781433457E

• Registered Funds:

  50 million yuan

• Email:

  Log in to view